Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), presented data evaluating safety margins of administration of deucrictibant immediate-release

ten23 health, the human-centric and sustainable strategic CDMO partner of choice for the pharmaceutical industry and biotech start-ups today announced the expansion of its commercial activities in the APAC area with the opening of a new office in Tokyo, Japan. This strategic move marks a significant milestone in the company’s global growth and further strengthens its ability to serve biotech and

New Offering Integrates DOPPL’s Patient-Derived Intestinal Organoid Technology with InSphero’s Proven Standardized Screening Model

Medistri, a leading provider of contract sterilization & laboratory services for healthcare companies, announces its enrollment in the Swiss Good Laboratory Practice (GLP) Compliance Monitoring Programme, effective 13 May 2026. The formal decision was issued by the Notification Authority for Chemicals (NAChem) at the Federal Office of Public Health, following inspections conducted by Swissme

Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026 Timeline for submission of NDA dossier of deucrictibant IR for on-demand treatment of HAE attacks remains on-track in 1H2026 Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH atta